Compounding BPC-157: A regulatory loophole In a statement, Health Canada said "BPC157 has not been authorized, its safety, efficacy, and quality have not been assessed and there is limited scientific evidence to support its use, including a lack of established human dosing protocols." In addition, the regulator says BPC-157 is not approved for use in any NHPs in any form, including oral and injectable, but it can still be compounded for topical use or oral administration as an NHP
Retatrutide is a triple agonist (GIP, GLP-1, and glucagon receptors) while Ozempic activates only GLP-1 receptors, resulting in significantly greater weight loss, 24.2% versus 14.9% at standard doses
$59.00 $99.99Price range: $59.00 through $99.99 BPC-157 is a 15amino acid peptide originally identified in gastric compounds
iThriveMD Encinitas Known For: iThriveMD offers peptide therapy in Encinitas, CA